Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 1/2016

01-01-2016 | Hepatobiliary Tumors

Loss of FOXF2 Expression Predicts Poor Prognosis in Hepatocellular Carcinoma Patients

Authors: Zhiyong Shi, MD, Jie Liu, MD, Xiaohe Yu, MD, Jian Huang, MD, Shuqun Shen, MD, Yongshun Zhang, MD, Rongli Han, MD, Naijian Ge, MD, Yefa Yang, MD

Published in: Annals of Surgical Oncology | Issue 1/2016

Login to get access

Abstract

Background

FOXF2 is a member of the forkhead box (FOX) family of transcription factors. FOXF2 plays an important role in several tumors but its expression and role in hepatocellular carcinoma (HCC) remains unknown.

Methods

Using immunohistochemistry, western blot, and real-time polymerase chain reaction, we analyzed FOXF2 expression in 295 clinicopathologically characterized HCC cases. Using RNA interference (RNAi), we investigated the effects of FOXF2 depletion on tumor cell behavior in vitro. Statistical analyses were used to determine associations between FOXF2 levels, tumor features, and patient outcomes.

Results

FOXF2 downregulation was observed in HCC tissues (p < 0.001) compared with peritumorous tissues, and its expression levels were closely correlated with overall survival and recurrence-free survival (p = 0.023 and 0.006, respectively) in patients with HCC. RNAi-mediated silencing of the FOXF2 gene in the MHCC-97H cell line significantly promoted proliferation and anti-apoptosis.

Conclusions

The results of the present study indicate that FOXF2 may serve as a prognostic biomarker for HCC and may be a promising target in the treatment of patients with HCC.
Literature
1.
A comment on ‘global activity of cancer registries and cancer control and cancer incidence statistics in Korea’. J Prev Med Public Health. 2008;41(3):208–209; author reply 209–11.
2.
Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15(Suppl 4):5–13.PubMedCrossRef
3.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRef
4.
Bruix J, Sherman M. American association for the study of liver diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.PubMedPubMedCentralCrossRef
5.
Katoh M, Katoh M. Human FOX gene family (review). Int J Oncol. 2004;25(5):1495–500.PubMed
6.
Badve S, Turbin D, Thorat MA, et al. FOXA1 expression in breast cancer: correlation with luminal subtype A and survival. Clin Cancer Res. 2007;13(15 Pt 1):4415–21.PubMedCrossRef
7.
Lo PK, Lee JS, Liang X, et al. Epigenetic inactivation of the potential tumor suppressor gene FOXF1 in breast cancer. Cancer Res. 2010;70(14):6047–58.PubMedPubMedCentralCrossRef
8.
Ray PS, Wang J, Qu Y, et al. FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res. 2010;70(10):3870–6.PubMedCrossRef
9.
Wolf I, Bose S, Williamson EA, Miller CW, Karlan BY, Koeffler HP. FOXA1: growth inhibitor and a favorable prognostic factor in human breast cancer. Int J Cancer. 2007;120(5):1013–22.PubMedCrossRef
10.
Gong C, Fujino K, Monteiro LJ, et al. FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer. Oncogene. doi:10.​1038/​onc.​2014.​421.
11.
Liu J, Shen L, Yao J, et al. Forkhead box C1 promoter upstream transcript, a novel long non-coding RNA, regulates proliferation and migration in basal-like breast cancer. Mol Med Rep. 2015;11(4):3155–9.PubMed
12.
Nik AM, Reyahi A, Ponten F, Carlsson P. Foxf2 in intestinal fibroblasts reduces numbers of Lgr5(+) stem cells and adenoma formation by inhibiting Wnt signaling. Gastroenterology. 2013;144(5):1001–11.PubMedCrossRef
13.
van der Heul-Nieuwenhuijsen L, Dits NF, Jenster G. Gene expression of forkhead transcription factors in the normal and diseased human prostate. BJU Int. 2009;103(11):1574–80.PubMedCrossRef
14.
Shi W, Gerster K, Alajez NM, et al. MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res. 2011;71(8):2926–37.PubMedCrossRef
15.
Kong PZ, Yang F, Li L, Li XQ, Feng YM. Decreased FOXF2 mRNA expression indicates early-onset metastasis and poor prognosis for breast cancer patients with histological grade II tumor. PloS One. 2013;8(4):e61591.PubMedPubMedCentralCrossRef
16.
17.
Hirata H, Ueno K, Shahryari V, et al. MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer. PloS One. 2013;8(1):e55502.PubMedPubMedCentralCrossRef
18.
19.
Funamizu N, Lacy CR, Parpart ST, Takai A, Hiyoshi Y, Yanaga K. MicroRNA-301b promotes cell invasiveness through targeting TP63 in pancreatic carcinoma cells. Int J Oncol. 2014;44(3):725–34.PubMed
20.
Cao G, Huang B, Liu Z, et al. Intronic miR-301 feedback regulates its host gene, ska2, in A549 cells by targeting MEOX2 to affect ERK/CREB pathways. Biochem Biophys Res Commun. 2010;396(4):978–82.PubMedCrossRef
21.
Aitola M, Carlsson P, Mahlapuu M, Enerback S, Pelto-Huikko M. Forkhead transcription factor FoxF2 is expressed in mesodermal tissues involved in epithelio-mesenchymal interactions. Dev Dyn. 2000;218(1):136–49.PubMedCrossRef
Metadata
Title
Loss of FOXF2 Expression Predicts Poor Prognosis in Hepatocellular Carcinoma Patients
Authors
Zhiyong Shi, MD
Jie Liu, MD
Xiaohe Yu, MD
Jian Huang, MD
Shuqun Shen, MD
Yongshun Zhang, MD
Rongli Han, MD
Naijian Ge, MD
Yefa Yang, MD
Publication date
01-01-2016
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 1/2016
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4515-2

Other articles of this Issue 1/2016

Annals of Surgical Oncology 1/2016 Go to the issue

Breast Oncology

Evaluation of the Clinical Utility of the ICG Fluorescence Method Compared with the Radioisotope Method for Sentinel Lymph Node Biopsy in Breast Cancer

Breast Oncology

Contralateral Prophylactic Mastectomy: Factors Predictive of Occult Malignancy or High-Risk Lesion and the Impact of MRI and Genetic Testing

Breast Oncology

Early Postoperative Outcomes in Breast Conservation Surgery Versus Simple Mastectomy with Implant Reconstruction: A NSQIP Analysis of 11,645 Patients

Colorectal Cancer

Treatment-Related Mortality After Cytoreductive Surgery and HIPEC in Patients with Colorectal Peritoneal Carcinomatosis is Underestimated by Conventional Parameters

Endocrine Tumors

Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes

Hepatobiliary Tumors

A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases